December 19, 2006 -- Progressive Multi-Focal Leukoencephalopathy (PML) was once a rare brain disease that few patients or even doctors had ever heard about. But it burst on the scene recently when it was found as a complication of the promising multiple sclerosis (MS) drug Tysabri. Now, PML has been found as a complication of Rituxan, another immuno-suppressant drug marketed by Genentech and Biogen. We examine the disease and its implications for Rituxan...
